- Home
- » Tags
- » Sacituzumab govitecan
Top View
- 5.01.540 (Effective Nov. 5, 2021) Miscellaneous Oncology Drugs
- Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
- Solid Tumor – Dr. Gralow TNBC
- Touchoncology Touchexpert OPINIONS Acds in Solid
- 10. Nurtec™ ODT (Rimegepant) 11
- The Oncology Market for Antibody–Drug Conjugates
- (PRIMO) Antibody-Drug Conjugate (ADC) Summit
- This Issue's News and Views
- Therapeutic Advances in Oncology
- Antibody–Drug Conjugates in Solid Tumors: a Look Into Novel Targets Carmen Criscitiello1,2, Stefania Morganti1,2 and Giuseppe Curigliano1,2*
- Oncology Medications Policy (1403)
- New Drug Report: 2Nd Quarter 2020
- An Overview of Antibody–Drug Conjugates in Oncological Practice
- Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Full Abbreviations, Accreditation, and Disclosure Information Available at Peerview.Com/EKR40
- JP Morgan Healthcare Conference Daniel O’Day Chairman and Chief Executive Officer
- Breast Cancer in Focus
- Highlights in Metastatic Breast Cancer from the European Society for Medical Oncology Virtual Congress 2020
- Approaches to the Treatment of Metastatic Bladder Cancer
- Clinical Criteria Updates
- A Closer Look at Sacituzumab Govitecan-Hziy
- Sacituzumab Govitecan-Hziy) for Injection, for Intravenous Use Reconstitution
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Antibody–Drug Conjugates for the Treatment of Breast Cancer
- Pipeline Report Report
- Evolving Therapies for Urothelial Carcinoma —Novel Paradigms and Future Directions
- Medical Drug Benefit Clinical Criteria Updates
- Antibody-Drug Conjugates: Simple Idea, Complicated Matter
- Crizanlizumab-Tmca
- (INN) for Biological and Biotechnological Substances
- 2020 FDA Drug Approvals Priority Reviews, for Products That Would the FDA Approved 53 Novel Drugs in 2020, the Second Highest Count in Over 20 Years
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Bladder Cancer
- Pipeline Report Recent Specialty Drug Approvals February 2020
- Asco Preview – a Second Wind for Antibody-Drug Conjugates
- The Pharmaceutical Industry in 2020. an Analysis of FDA Drug Approvals from the Perspective of Molecules
- Diplomat Specialty Pipeline Report
- Medical Drug Benefit Clinical Criteria Updates
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- Targeted Molecular Therapeutics for Bladder Cancer—A New Option Beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
- Sacituzumab Govitecan-Hziy) for Injection, for Intravenous Use Reconstitution
- Provider Bulletin Clinical Criteria Updates
- Therapeutic Monoclonal Antibodies Approved by FDA in 2020 Henry Hongrong Cai, MD
- Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Antibodies to Watch in 2018